BRAF V600E is the defining molecular lesion of classic hairy cell leukemia (~100% of cHCL...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600E-HCL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-HCL |
| Sources | SRC-CIVIC SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600E |
| Disease | DIS-HCL |
| ESCAT tier | IB |
| Recommended combinations | vemurafenib monotherapy (R/R cHCL), vemurafenib + rituximab (consolidation / R/R), dabrafenib + trametinib (alternative) |
| Evidence summary | BRAF V600E is the defining molecular lesion of classic hairy cell leukemia (~100% of cHCL; absent in HCL-variant). Vemurafenib monotherapy yields CR ~35% / ORR ~96% in relapsed/refractory cHCL (Tiacci et al. NEJM 2015). Vemurafenib + rituximab gives durable CR in ~87% (Tiacci et al. NEJM 2021). Dabrafenib + trametinib also active. Used as salvage after purine-analog failure or in cladribine-ineligible patients. |
Notes
ESCAT IB. OncoKB Level 2. Frontline cHCL still cladribine ± rituximab (MDACC) — BRAFi reserved for relapsed/refractory or unfit patients. HCL-variant lacks BRAF V600E and is BRAFi-resistant.
Used By
No reverse references found in the YAML corpus.